ATE384520T1 - Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas - Google Patents

Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas

Info

Publication number
ATE384520T1
ATE384520T1 AT04720007T AT04720007T ATE384520T1 AT E384520 T1 ATE384520 T1 AT E384520T1 AT 04720007 T AT04720007 T AT 04720007T AT 04720007 T AT04720007 T AT 04720007T AT E384520 T1 ATE384520 T1 AT E384520T1
Authority
AT
Austria
Prior art keywords
fibrate
orlistat
obesitas
treatment
combined use
Prior art date
Application number
AT04720007T
Other languages
English (en)
Inventor
Alan Edgar
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Application granted granted Critical
Publication of ATE384520T1 publication Critical patent/ATE384520T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
AT04720007T 2003-03-13 2004-03-12 Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas ATE384520T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03290625A EP1457206A1 (de) 2003-03-13 2003-03-13 Kombinierte Verwendung von einem Fibrat und von Orlistat zur Behandlung von Obesitas

Publications (1)

Publication Number Publication Date
ATE384520T1 true ATE384520T1 (de) 2008-02-15

Family

ID=32749013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720007T ATE384520T1 (de) 2003-03-13 2004-03-12 Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas

Country Status (19)

Country Link
US (1) US20070078179A1 (de)
EP (2) EP1457206A1 (de)
JP (1) JP4928256B2 (de)
CN (1) CN100562313C (de)
AT (1) ATE384520T1 (de)
AU (1) AU2004218938B2 (de)
BR (1) BRPI0408322A (de)
CA (1) CA2518205C (de)
DE (1) DE602004011486T2 (de)
DK (1) DK1601352T3 (de)
EA (1) EA009127B1 (de)
ES (1) ES2300750T3 (de)
HK (1) HK1083767A1 (de)
IL (1) IL170519A (de)
MX (1) MXPA05009718A (de)
NO (1) NO20054700L (de)
PT (1) PT1601352E (de)
WO (1) WO2004080450A2 (de)
ZA (1) ZA200507227B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
EP2625968A1 (de) * 2007-09-12 2013-08-14 Københavns Universitet Zusammensetzungen und methoden zur verstärkung der hungerunterdrückung und zum reduzieren der verdaulichkeit der nichtfettenergiesättigung
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
WO2011130302A2 (en) 2010-04-12 2011-10-20 Reata Pharmaceuticals, Inc. Method of treating obesity using antioxidant inflammation modulators
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
CA2895827A1 (en) * 2012-12-21 2014-06-26 Merck Patent Gmbh Magnesium hydroxide carbonate as excipient in pharmaceutical preparations having improved release of active ingredient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
TW438784B (en) * 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
WO2001060807A1 (en) * 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
EP1424070A1 (de) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Senkung des Serumtriglyceridspiegels

Also Published As

Publication number Publication date
US20070078179A1 (en) 2007-04-05
EA009127B1 (ru) 2007-10-26
CN100562313C (zh) 2009-11-25
IL170519A0 (en) 2006-10-05
NO20054700L (no) 2005-10-12
AU2004218938B2 (en) 2009-04-09
CA2518205A1 (en) 2004-09-23
BRPI0408322A (pt) 2006-03-14
WO2004080450A2 (en) 2004-09-23
CA2518205C (en) 2012-05-08
CN1826108A (zh) 2006-08-30
PT1601352E (pt) 2008-04-07
MXPA05009718A (es) 2005-10-18
DK1601352T3 (da) 2008-05-13
ES2300750T3 (es) 2008-06-16
WO2004080450A3 (en) 2005-02-24
EP1601352A2 (de) 2005-12-07
HK1083767A1 (en) 2006-07-14
AU2004218938A1 (en) 2004-09-23
IL170519A (en) 2010-12-30
DE602004011486D1 (de) 2008-03-13
DE602004011486T2 (de) 2009-01-15
JP2006520365A (ja) 2006-09-07
EP1601352B1 (de) 2008-01-23
EP1457206A1 (de) 2004-09-15
EA200501259A1 (ru) 2006-02-24
JP4928256B2 (ja) 2012-05-09
ZA200507227B (en) 2006-11-29

Similar Documents

Publication Publication Date Title
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60327074D1 (de) Fluorobenzamide zur behandlung von alzheimer oder seniler dementia
ATE472329T1 (de) Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis
NO20054700L (no) Anvendelse av et fibrat og orlistat for behandling av fedme
DE60219687D1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
ATE361755T1 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE408602T1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
ATE427754T1 (de) Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen
ATE498397T1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
DE60219495D1 (de) Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten
DE602004026830D1 (de) Verwendung von pvp-iod liposomen zur behandlung von atopischer dermatitis
ATE386748T1 (de) Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE401321T1 (de) Beta-lactame zur behandlung von erkrankungen des zns
ATE476185T1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
DE60321377D1 (de) Verwendung von levocetirizin zur behandlung von persistierender allergischer rhinitis
DE10311984A8 (de) Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1601352

Country of ref document: EP